Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Percutaneous Occluding of the Left Atrium

Evolution of Microparticles Circulating Plasma Concentration in Atrial Fibrillation After Percutaneous Occluding of the Left Atrium With Prosthesis (Amplatzer® Cardiac Plug)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03361202

Acronym

MICROPLUG

Enrollment

Registered

2017-12-04

Start date

2015-01-31

Completion date

2018-03-31

Last updated

2017-12-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Fibrillation

Brief summary

The aim of the study is to compare levels of differnts types of microparticles circulating before and after percutaneous occluding of the left atrium by patients with atrial fibrillation and patients control. Hypothesis is that prothesis implantation will decrease levels of microparticles circulating in blood circulation because of occluding of the left atrium .

Interventions

OTHERblood sampling

* atrial fibrillation group:before Percutaneous Occluding of the Left Atrium, at hospital discharge and at J45 follow up * control group:before coronary angiography and at hospital discharge.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

atrial fibrillation group: * high embolic risk (CHADS-VASC2 score ≥4) * formal and final contraindication to anticoagulant therapy * no heart thrombus on ETO and TDM before percuraneous occluding control group: * suspicion of stable coronary artery disease, coronary angiography scheduled and double platelet aggregation (clopidogrel and aspirine)

Exclusion criteria

for both groups * congestive heart failure, severe aortic stenosis, EP or TVP early.

Design outcomes

Primary

Measure	Time frame	Description
levels of microparticles expressing phosphatidylserine in atrial fibrillation group	45 days after Percutaneous Occluding of the Left Atrium.	blood samples analized by flow cytometry

Countries

France

Contacts

Primary ContactNicolas AMABILE, doctor

nicolas.amabile@imm.fr+33 1 56 61

Backup ContactIsabelle SAURET

isabelle.sauret@imm.fr+33 1 56 61 67 05

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026